Richard Hall, MD
Adolescent Medicine · Mount Sterling, KYNPI 1134178353
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,817 of the $2,238 with a category attached, or 81.2%. It is spread thinly across 30 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $591 and has fallen 66.4% since, to $199 in 2025. Among adolescent medicine clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 93 payments — averaging $24.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Midmark Corporation$426
- Supernus Pharmaceuticals, Inc.$378
- GSK$258
- AbbVie$180
- Novo Nordisk$159
- Pfizer$108
- plus $729 from 24 others
What the payments were for
- Travel & lodging$38617%
- Food & beverage$1,81781%
- Education$362%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Midmark Corporation | 2 | $426 |
| Supernus Pharmaceuticals, Inc. | 1 | $378 |
| GSK | 15 | $258 |
| AbbVie(2 entities) | 11 | $180 |
| Novo Nordisk | 11 | $159 |
| Pfizer | 8 | $108 |
| Gilead | 3 | $71 |
| Merck | 5 | $69 |
| Corium, LLC | 4 | $64 |
| AstraZeneca | 4 | $58 |
| Teva Pharmaceuticals USA, Inc. | 4 | $58 |
| Lilly USA, LLC | 3 | $49 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Novartis | 2 | $29 |
| Bayer | 2 | $28 |
| Seqirus USA Inc | 1 | $27 |
| Neurocrine Biosciences, Inc. | 1 | $26 |
| Boehringer Ingelheim | 2 | $25 |
| Tris Pharma Inc | 1 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
| Sage Therapeutics, LLC | 1 | $20 |
| Neuronetics, Inc. | 2 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Abbott | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Hologic Sales And Service, LLC | 1 | $14 |
| Exact Sciences | 1 | $13 |
| Bardy Diagnostics, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$378
How this compares
$2,238 in reported general payments places this provider in the 90th percentile of 39 adolescent medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 56 | $76,127 |
| EliquisApixaban | 61 | $55,885 |
| OzempicSemaglutide | 35 | $53,485 |
| FarxigaDapagliflozin Propanediol | 34 | $40,129 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $36,446 |
| XareltoRivaroxaban | 19 | $24,821 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $16,129 |
| GlyxambiEmpagliflozin/Linagliptin | 17 | $14,590 |
| MounjaroTirzepatide | 13 | $13,364 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 15 | $4,079 |
| Novolog FlexpenInsulin Aspart | 11 | $3,808 |
| Gabapentin | 245 | $3,105 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 184 | $2,462 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 13 | $2,448 |
| Ventolin HfaAlbuterol Sulfate | 21 | $2,075 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi | $25 | $90,71773 claims |
| PfizerEliquis | $108 | $55,88561 claims |
| Novo NordiskOzempic | $159 | $53,48535 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix | $258 | $42,97450 claims |
| AstraZenecaFarxiga | $58 | $40,12934 claims |
| Johnson & JohnsonXarelto | $20 | $24,82119 claims |
| Lilly USA, LLCMounjaro | $49 | $13,36413 claims |
| AbbVieSynthroid | $180 | $74019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 39 adolescent medicine providers in Kentucky.
Other adolescent medicine in Mount Sterling
- Stephen BessonCynthiana$12K
- Jeffrey McGinnisMt Sterling$4K
- Thomas McCormickLouisville$3K
- Ashli Collinsla Grange$2K
- James CalderCynthiana$2K
- Brian GillispieLexington$1K
- Katrina HoodLexington$1K
- Gregory TracyLexington$1K
- Debra BaileyPikeville$940
- Charles IsonLexington$858
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.